NASDAQ:AVXL Anavex Life Sciences Q2 2026 Earnings Results & Report $1.49 -0.05 (-3.25%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.53 +0.04 (+2.68%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Anavex Life Sciences beat analyst earnings expectations in its Q2 2026 results, released August 25, 2026. The company reported EPS of $0.08 versus the -$0.08 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 25, 2026TimeAfter Market Closes Anavex Life Sciences EPS ResultsActual EPS$0.08Consensus EPS -$0.08Beat/MissBeat by +$0.16One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersAnavex Life Sciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAnavex Life Sciences' Q4 2026 earnings is estimated for Tuesday, November 24, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Anavex Life Sciences Q2 2026 Earnings FAQ Did Anavex Life Sciences beat earnings estimates for Q2 2026? Anavex Life Sciences (NASDAQ:AVXL) reported earnings of $0.08 per share for Q2 2026, beating the consensus estimate of -$0.08. The report was announced on Tuesday, August 25, 2026. When is Anavex Life Sciences' next earnings date? Anavex Life Sciences' next earnings date is estimated for Tuesday, November 24, 2026. MarketBeat tracks confirmed and estimated earnings dates for Anavex Life Sciences on the company's earnings history page. Anavex Life Sciences Earnings HeadlinesAnavex Life Sciences (NASDAQ:AVXL) Stock Price Crosses Below 50-Day Moving Average - Should You Sell?October 9 at 4:01 AM | americanbankingnews.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXLOctober 8 at 8:12 PM | globenewswire.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live. | Banyan Hill Publishing (Ad)Deadline Alert: Anavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitOctober 8 at 2:00 PM | businesswire.comAnavex Life Sciences Corp. (AVXL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 8 at 1:30 PM | prnewswire.comSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 30, 2026 in Anavex Life Sciences Corp. Lawsuit - AVXLOctober 8 at 10:11 AM | prnewswire.comSee More Anavex Life Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anavex Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anavex Life Sciences and other key companies, straight to your email. Email Address About Anavex Life SciencesAnavex Life Sciences (NASDAQ:AVXL) (NASDAQ: AVXL) is a clinical-stage biotechnology company focused on developing pharmaceutical therapies for central nervous system disorders. The company’s research is centered on small-molecule compounds intended to address cellular pathways associated with neurodegeneration and other neurological conditions. Anavex’s lead product candidate is blarcamesine (ANAVEX2-73), an orally administered investigational therapy designed to activate the sigma-1 receptor and modulate muscarinic receptors. The company has evaluated blarcamesine in clinical studies for Alzheimer’s disease, Rett syndrome and Parkinson’s disease dementia. Anavex is also developing additional investigational compounds, including ANAVEX3-71, for potential use in neurodegenerative diseases. These candidates have not been approved as treatments by regulatory authorities. Founded in 2006, Anavex Life Sciences conducts research and clinical development activities through collaborations and trials in multiple regions, including the United States, Australia and Europe. The company is led by Christopher U. Missling, Ph.D., who serves as president and chief executive officer.View Anavex Life Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
